IGFBP-2 is up-regulated in an in vitro model of Her-2+ BC [44] and recently multiple antigenic peptides (MAPs) comprising IGFBP-2 epitopes have been used to block tumour progression in a transgenic mouse model [37, 45]. Here, IGFBP2 is linked to breast cancer.